Improving Biological Age, Telomere Length, and Cognition: A Case Report on the Use of Therapeutic Plasma Exchange, Peptides, Umbilical Cord Tissue Mesenchymal Stem Cells and Exosomes in a Patient with Cognitive Decline

Objective: This case study reports on the novel combination of three treatments for cognitive decline in a 79-year-old male: therapeutic plasma exchange (TPE), peptides, and human umbilical cord tissue mesenchymal stem cells and exosomes (UCT-MSC-EXs). Methods: Cognitive function was evaluated with the Central Nervous System-Vital Signs (CNS-VS) test. Biological age and telomere lengths were measured at baseline, 9 months, and 16 months using TruAge. The patient received four rounds of TPE (5% albumin exchange) administered using the Amicus Separator. He was also treated with UCT-MSC-EXs manufactured by Vitti Labs (Liberty, MO, USA). In addition, he was given two peptides, Semax and Epitalon, to address cognitive decline. Results: After 1 year of treatment using TPE with 5% albumin, UCT-MSC-EXs, Semax and Epitalon, the patient’s biological age was reduced by 7.9 years (from 75.93 to 68.03), and his telomere length increased from 6.45 to 6.59 kb. As the CNS-VS test documented, his cognitive function improved from April 2022 to December 2023. Conclusion: To our knowledge, this is the first case study to report on reducing biological age, increasing telomere length, and improving cognition using this unique combination of therapies in a patient with mild to moderate cognitive decline.